European Primary Care Cardiovascular Society

COVID-19

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 2, 2022 - Prof. Richard Hobbs, MD

"During the pandemic, we have lost sight of long-term conditions that are the biggest contributors to worse outcomes", says prof. Hobbs. "We need to restart and catch up in CVD prevention ASAP."

2022 ACC expert consensus pathway on cardiovascular sequelae of COVID-19

News - Mar. 24, 2022

The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.

Increased risk of long-term CV outcomes after COVID-19

Literature - Feb. 15, 2022 - Xie Y et al. - Nat Med. 2022

A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.

Signs of affection of multi-organ systems after recovery from mild to moderate COVID-19

Literature - Jan. 20, 2022 - Petersen EL, et al. - Eur Heart J 2021

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

After COVID-19 hospitalization extended thromboprophylaxis with DOAC improves outcomes

Literature - Jan. 11, 2022 - Ramacciotti E, et al. - Lancet 2022

The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the DOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.

ESC Guidance document on diagnosis and treatment of CVD during the COVID-19 pandemic

News - Dec. 6, 2021

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

Highly-purified icosapent ethyl does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

No improvement of outcomes with therapeutic-dose of heparin in critically ill COVID-19 patients

Literature - Aug. 16, 2021 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, et al. - NEJM 2021
In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

COVID-19 vaccine-induced atypical thrombosis and thrombocytopenia in some individuals

Literature - Apr. 26, 2021 - Scully M, et al. - N Engl J Med. 2021 Apr 16.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Some cases after COVID-19 vaccination show clinical resemblance of heparin-induced thrombocytopenia

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD
Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications in hospitalized COVID-19 patients remained high in second wave

Literature - Mar. 5, 2021 - Kaptein FHJ et al., - Thrombosis Research 2020.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

COVID-19